Does Teva's Terrible Tumble Make Its Stock a Buy?

Disappointing financial results, a dividend cut, and reduced guidance have caused Teva Pharmaceutical Industries (NYSE: TEVA) shares to lose half their value in the past month. Can a restructuring help management reduce debt and kick-start shares, or is this company's share price on its way to zero?

In this clip from the Motley Fool's Industry Focus: Healthcare podcast, analyst Kristine Harjes and contributor Todd Campbell explain why Teva Pharmaceutical's share price is tumbling and if investors should be bargain hunting or avoiding this company's stock.

A full transcript follows the video.

Source: Fool.com